Abstract：Objective: To investigate and analyze the relative expression and clinical significance of long non coding RNA metastasis associated lung adenocarcinoma transcript 1 (LncRNA MALAT1) and microribonucleic acid (miR)-143-3p in thyroid cancer tissue. Methods: From September 2019 to February 2021, 102 patients with thyroid cancer admitted to our hospital were recruited. They were grouped into the survival group (n=71) and death group (n=31) based on their follow-up results. Real-time reverse transcription-polymerase chain reaction (RT-PCR) was applied to detect the relative expression levels of LncRNA MALAT1 and miR-143-3p in tissues. General clinical data and clinical pathological features were collected and analyzed. Pearson method was used to analyze the correlation between LncRNA MALAT1 and miR-143-3p. STARbase was employed to predict the targeting relationship between LncRNA MALAT1 and miR-143-3p. COX was performed to analyze the influencing factors of prognosis. K-M curve was plotted to analyze the relationship between LncRNA MALAT1, miR-143-3p and survival. Results: Compared with those of adjacent tissues, the relative expression level of LncRNA MALAT1 was significantly increased (P<0.05) and the relative expression level of miR-143-3p was significantly reduced in cancer tissues (P<0.05). The expression of LncRNA MALAT1 and miR-143-3p was related to tumor diameter, tumor-node-metastasis (TNM) stage, differentiation degree, and lymph node metastasis (P<0.05). There was a negative correlation between LncRNA MALAT1 and miR-143-3p (r=-0.408, P<0.05), and there was a targeting relationship between LncRNA MALAT1 and miR-143-3p. The differences were statistically significant in TNM staging, differentiation degree, lymph node metastasis, LncRNA MALAT1, and miR-143-3p expression between groups (P<0.05). Lymph node metastasis and increased expression of LncRNA MALAT1 were risk factors affecting patient prognosis (P<0.05), while miR-143-3p was a protective factor (P<0.05). The survival rate of patients with low expression of LncRNA MALAT1 was significantly higher than that of patients with high expression (80.85% [38/47] vs 60.00% [33/55] , χ2=6.597, P=0.010). The survival rate of patients with high expression of miR-143-3p was significantly higher than that of patients with low expression (81.63% [40/49] vs 58.49% [31/53], χ2=8.509, P=0.004). Conclusion: In thyroid cancer tissue, the relative expression of LncRNA MALAT1 increases and the relative expression of miR-143-3p decreases, which is related to clinical pathological characteristics and has a certain impact on prognosis.
金栋, 刘永丽. LncRNA MALAT1 miR-143-3p在甲状腺癌组织中的表达水平及其临床意义[J]. 河北医学, 2025, 31(3): 408-414.
JIN Dong, LIU Yongli. Expression Levels and Clinical Significance of LncRNA MALAT1 and miR-143-3p in Thyroid Cancer Tissue. HeBei Med, 2025, 31(3): 408-414.
[1] 黎思毅,覃文懿,郑昌蔚,等.CXC趋化因子受体7和B7-H4在甲状腺癌组织的表达及其临床意义[J].中华实验外科杂志,2023,40(1):134-137. [2] Agosto Salgado S,Kaye ER,Sargi Z,et al.Management of advanced thyroid cancer:overview,advances,and opportunities[J].Am Soc Clin Oncol Educ Book,2023,43(1):389708. [3] Wang Y,Zhang J,Shi H,et al.M2 Tumor-associated macrophages-derived exosomal MALAT1 promotes glycolysis and gastric cancer progression[J].Adv Sci (Weinh),2024,11(24):e2309298. [4] Wang ZL,Wang C,Liu W,et al.Upregulation of microRNA-143-3p induces apoptosis and suppresses proliferation,invasion,and migration of papillary thyroid carcinoma cells by targeting MSI2[J].Exp Mol Pathol,2020,112(1):104342. [5] Qu N,Hui Z,Shen Z,et al.Thyroid cancer and COVID-19:prospects for therapeutic approaches and drug development[J].Front Endocrinol (Lausanne),2022,13(1):873027-873039. [6] Han PZ,Ye WD,Yu PC,et al.A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer[J].JCI Insight,2024,9(8):173712. [7] Jiang H,Li Y,Shen J,et al.Cigarette smoking and thyroid cancer risk:a mendelian randomization study[J].Cancer Med,2023,12(19):19866-19873. [8] Zhu G,Chang X,Kang Y,et al.CircRNA:a novel potential strategy to treat thyroid cancer (Review)[J].Int Mol Med,2021,48(5):201-213. [9] 明旭,张婷婷.微小RNA-1303和神经调节蛋白1在甲状腺癌组织中的表达及其临床意义[J].中国医药,2022,17(5):683-687. [10] Yi S,Liu L,Chen Z.LncRNA EGFEM1P promotes thyroid cancer progression by acting as an miR-369-3p sponge and upregulating TCF4[J].Oncol Lett,2022,24(6):456-464. [11] Hao L,Wu W,Xu Y,et al.LncRNA-MALAT1:A key participant in the occurrence and development of cancer[J].Molecules,2023,28(5):2126-2139. [12] Ye M,Dong S,Hou H,et al.Oncogenic role of long noncoding RNAMALAT1 in thyroid cancer progression through regulation of the miR-204/IGF2BP2/m6A-MYC signaling[J].Mol Ther Nucleic Acids,2020,23(1):1-12. [13] Khan R,Abbasi SA,Mansoor Q,et al.Analysis of rare alleles of miRNA-146a (rs2910164) and miRNA-34b/c (rs4938723) as a prognostic marker in thyroid cancer in pakistani population[J].Diagnostics (Basel),2022,12(10):2495-2504. [14] Armstrong L,Willoughby CE,McKenna DJ.Targeting of AKT1 by miR-143-3p suppresses epithelial-to-mesenchymal transition in prostate cancer[J].Cells,2023,12(18):2207-2224. [15] Wang Y,Zhou S,Zhao W,et al.Association between functional polymorphisms in the flanking region of miR-143/145 and risk of papillary thyroid carcinoma:a case-control study[J].Medicine (Baltimore),2020,99(49):23560.
2025, Vol. 31 
冀公网安备13080202000786号